One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Investigating Racial and Ethnic Disparities Along the Care Cascade for Older Adults Newly Diagnosed With Metastatic Cancer.
doi : 10.1200/JCO-25-01613
Volume 43(30) pgs. 3233-3325,e60-e70 October 20, 2025
Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.
doi : 10.1200/JCO-25-01148
Treat the Tumor, Spare the Esophagus: The Case for Organ Preservation in Locally Advanced Esophageal/Gastroesophageal Junction Cancer.
doi : 10.1200/JCO-25-01197
Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.
doi : 10.1200/JCO-25-00040
Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers.
doi : 10.1200/JCO-24-02440
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.
doi : 10.1200/JCO-24-01502
Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer.
doi : 10.1200/JCO-24-02816
Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline.
doi : 10.1200/JCO-25-01747
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.
doi : 10.1200/JCO-25-00167
Reply to: "Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer" and "CDK4/6 Inhibitors in Estrogen Receptor-Low Breast Cancer".
doi : 10.1200/JCO-25-01688
Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.
doi : 10.1200/JCO-25-02195
